by Karen O'Hanlon Cohrt | Feb 18, 2024 | Trends
Organoids are cell-derived, 3D in vitro models that are cultured to recapitulate structural and functional aspects of the in vivo tissue they are intended to represent. Organoids are not new to research labs, although there has been much hype about them in recent...
by Karen O'Hanlon Cohrt | Dec 26, 2023 | Disease Models
It’s a fibroblast-like cell adorned with long cytoplasmic processes that wrap around the endothelial cells in blood vessels, it controls blood flow through the blood vessels, and it is essential for normal brain function and development. Which cell type is it? Well,...
by Karen O'Hanlon Cohrt | Nov 21, 2023 | Industry News, Trends
Antibody drug conjugates (ADCs) are targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. In contrast to conventional chemotherapies, which do not discriminate between healthy and cancerous cells, ADCs are...
by Karen O'Hanlon Cohrt | Sep 24, 2023 | Disease Models
In our last few liver articles, we highlighted the urgent need for new models and treatments for non-alcoholic steatohepatitis (NASH), and looked at the potential for human liver organoids to not only model disease, but also to test new drugs for safety and efficacy....
by Karen O'Hanlon Cohrt | Jul 18, 2023 | Disease Models
The lack of approved treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatosis (NASH) is largely explained by the shortcomings of cellular models used to unravel disease mechanisms, identify and validate new drug targets, and screen...
